These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 22386565)

  • 21. Synthesis and biological characterization of B-ring amino analogues of potent benzothiadiazine hepatitis C virus polymerase inhibitors.
    Randolph JT; Flentge CA; Huang PP; Hutchinson DK; Klein LL; Lim HB; Mondal R; Reisch T; Montgomery DA; Jiang WW; Masse SV; Hernandez LE; Henry RF; Liu Y; Koev G; Kati WM; Stewart KD; Beno DW; Molla A; Kempf DJ
    J Med Chem; 2009 May; 52(10):3174-83. PubMed ID: 19402666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a series of novel derivatives as potent HCV inhibitors by a ligand-based virtual screening optimized procedure.
    Melagraki G; Afantitis A; Sarimveis H; Koutentis PA; Markopoulos J; Igglessi-Markopoulou O
    Bioorg Med Chem; 2007 Dec; 15(23):7237-47. PubMed ID: 17869118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of unsymmetrical 1-hydroxy-4,4-dialkyl-3-oxo-3,4-dihydronaphthalene benzothiadiazine derivatives.
    Krueger AC; Madigan DL; Green BE; Hutchinson DK; Jiang WW; Kati WM; Liu Y; Maring CJ; Masse SV; McDaniel KF; Middleton TR; Mo H; Molla A; Montgomery DA; Ng TI; Kempf DJ
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2289-92. PubMed ID: 17300933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of potential inhibitors for HCV NS5b of genotype 4a by combining dynamic simulation, protein-ligand interaction fingerprint, 3D pharmacophore, docking and 3D QSAR.
    El-Hassab MAE; El-Bastawissy EE; El-Moselhy TF
    J Biomol Struct Dyn; 2020 Sep; 38(15):4521-4535. PubMed ID: 31647392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
    Chen CM; He Y; Lu L; Lim HB; Tripathi RL; Middleton T; Hernandez LE; Beno DW; Long MA; Kati WM; Bosse TD; Larson DP; Wagner R; Lanford RE; Kohlbrenner WE; Kempf DJ; Pilot-Matias TJ; Molla A
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4290-6. PubMed ID: 17908950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anthranilic acid-based Thumb Pocket 2 HCV NS5B polymerase inhibitors with sub-micromolar potency in the cell-based replicon assay.
    Stammers TA; Coulombe R; Duplessis M; Fazal G; Gagnon A; Garneau M; Goulet S; Jakalian A; LaPlante S; Rancourt J; Thavonekham B; Wernic D; Kukolj G; Beaulieu PL
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6879-85. PubMed ID: 24176401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate.
    McKercher G; Beaulieu PL; Lamarre D; LaPlante S; Lefebvre S; Pellerin C; Thauvette L; Kukolj G
    Nucleic Acids Res; 2004; 32(2):422-31. PubMed ID: 14739234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pyridobenzothiazole derivatives as new chemotype targeting the HCV NS5B polymerase.
    Manfroni G; Meschini F; Barreca ML; Leyssen P; Samuele A; Iraci N; Sabatini S; Massari S; Maga G; Neyts J; Cecchetti V
    Bioorg Med Chem; 2012 Jan; 20(2):866-76. PubMed ID: 22197397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tri-substituted acylhydrazines as tertiary amide bioisosteres: HCV NS5B polymerase inhibitors.
    Canales E; Carlson JS; Appleby T; Fenaux M; Lee J; Tian Y; Tirunagari N; Wong M; Watkins WJ
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4288-92. PubMed ID: 22664130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 1: exploration of 7'-substitution of benzothiadiazine.
    Zhou Y; Webber SE; Murphy DE; Li LS; Dragovich PS; Tran CV; Sun Z; Ruebsam F; Shah AM; Tsan M; Showalter RE; Patel R; Li B; Zhao Q; Han Q; Hermann T; Kissinger CR; Lebrun L; Sergeeva MV; Kirkovsky L
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1413-8. PubMed ID: 18242088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-nucleoside inhibitors of NS5B polymerase binding to allosteric sites: 3D- QSAR and molecular docking studies.
    Cao H; Cao R; Zhang H; Zheng X; Gao D
    Curr Med Chem; 2008; 15(15):1462-77. PubMed ID: 18537623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular modeling and residue interaction network studies on the mechanism of binding and resistance of the HCV NS5B polymerase mutants to VX-222 and ANA598.
    Xue W; Jiao P; Liu H; Yao X
    Antiviral Res; 2014 Apr; 104():40-51. PubMed ID: 24462692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A highly selective structure-based virtual screening model of Palm I allosteric inhibitors of HCV Ns5b polymerase enzyme and its application in the discovery and optimization of new analogues.
    Mahmoud AH; Abou El Ella DA; Ismail MA; Abouzid KA
    Eur J Med Chem; 2012 Nov; 57():468-82. PubMed ID: 22824204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interference of HCV replication by cell penetrable human monoclonal scFv specific to NS5B polymerase.
    Thueng-in K; Thanongsaksrikul J; Jittavisutthikul S; Seesuay W; Chulanetra M; Sakolvaree Y; Srimanote P; Chaicumpa W
    MAbs; 2014; 6(5):1327-39. PubMed ID: 25517317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C virus (HCV) NS5B nonnucleoside inhibitors specifically block single-stranded viral RNA synthesis catalyzed by HCV replication complexes in vitro.
    Yang W; Sun Y; Phadke A; Deshpande M; Huang M
    Antimicrob Agents Chemother; 2007 Jan; 51(1):338-42. PubMed ID: 17088480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of an irreversible HCV NS5B polymerase inhibitor.
    Zeng Q; Nair AG; Rosenblum SB; Huang HC; Lesburg CA; Jiang Y; Selyutin O; Chan TY; Bennett F; Chen KX; Venkatraman S; Sannigrahi M; Velazquez F; Duca JS; Gavalas S; Huang Y; Pu H; Wang L; Pinto P; Vibulbhan B; Agrawal S; Ferrari E; Jiang CK; Li C; Hesk D; Gesell J; Sorota S; Shih NY; Njoroge FG; Kozlowski JA
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6585-7. PubMed ID: 24252545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and Docking.
    Wei Y; Li J; Qing J; Huang M; Wu M; Gao F; Li D; Hong Z; Kong L; Huang W; Lin J
    PLoS One; 2016; 11(2):e0148181. PubMed ID: 26845440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of substituted N-phenylbenzenesulphonamides as a novel class of non-nucleoside hepatitis C virus polymerase inhibitors.
    May MM; Brohm D; Harrenga A; Marquardt T; Riedl B; Kreuter J; Zimmermann H; Ruebsamen-Schaeff H; Urban A
    Antiviral Res; 2012 Aug; 95(2):182-91. PubMed ID: 22580131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HCV NS5B polymerase inhibitors 1: Synthesis and in vitro activity of 2-(1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl)-1-hydroxynaphthalene derivatives.
    Wang G; He Y; Sun J; Das D; Hu M; Huang J; Ruhrmund D; Hooi L; Misialek S; Ravi Rajagopalan PT; Stoycheva A; Buckman BO; Kossen K; Seiwert SD; Beigelman L
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4476-9. PubMed ID: 19502055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors.
    Stammers TA; Coulombe R; Rancourt J; Thavonekham B; Fazal G; Goulet S; Jakalian A; Wernic D; Tsantrizos Y; Poupart MA; Bös M; McKercher G; Thauvette L; Kukolj G; Beaulieu PL
    Bioorg Med Chem Lett; 2013 May; 23(9):2585-9. PubMed ID: 23545108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.